KR101929664B1 - Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof - Google Patents
Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof Download PDFInfo
- Publication number
- KR101929664B1 KR101929664B1 KR1020170066486A KR20170066486A KR101929664B1 KR 101929664 B1 KR101929664 B1 KR 101929664B1 KR 1020170066486 A KR1020170066486 A KR 1020170066486A KR 20170066486 A KR20170066486 A KR 20170066486A KR 101929664 B1 KR101929664 B1 KR 101929664B1
- Authority
- KR
- South Korea
- Prior art keywords
- white ginseng
- ginseng
- present
- extract
- white
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명에 따른 백삼 추출물은 펙티나제 효소를 이용하여 제조함으로써 백삼으로부터 유래한 진세노사이드 Rd, Rg3 및 Rg5 성분이 강화된 항산화 효능을 나타내는 식품 조성물 또는 약학 조성물로 다양하게 활용할 수 있다. The white ginseng extract according to the present invention can be variously used as a food composition or a pharmaceutical composition exhibiting antioxidative activity enhanced by the ginsenoside Rd, Rg3 and Rg5 components derived from white ginseng by using pectinase enzyme.
Description
본 발명은 진세노사이드 Rd, Rg3 및 Rg5 함량이 강화된 백삼 추출물에 관한 것으로, 더욱 상세하게는 효소를 이용하여 백삼 추출물을 제조함으로써 백삼으로부터 유래한 진세노사이드 Rd, Rg3 및 Rg5 성분이 강화된 항산화 효능을 가지는 식품 및 약학 조성물에 관한 것이다.The present invention relates to a white ginseng extract having enhanced contents of ginsenosides Rd, Rg3 and Rg5, and more particularly, to a white ginseng extract obtained by preparing white ginseng extract using an enzyme, wherein the ginsenoside Rd, Rg3 and Rg5 components And to food and pharmaceutical compositions having antioxidant efficacy.
인삼(Panax ginseng C.A. Meyer)은 오가피과 인삼 속에 속하는 식물로 한국, 중국 및 일본 등지에서 2,000여 년 전부터 사용되어 온 생약으로, 경험적으로 질병을 예방하고 수명을 연장 시킬 목적으로 사용되어 왔다. 지금까지 알려진 인삼의 효능 및 효과는 항암 작용, 면역기능 조절 작용, 항당뇨 작용, 간기능 항진 작용, 심혈관 장해개선, 항동맥경화 작용, 혈압조절 작용, 갱년기 장애 개선, 항스트레스 및 항피로 작용, 항산화 활성 및 노화억제 작용 등이 있다(최신고려인삼 '성분 및 효능편', 한국인삼연초연구원, 56-112, 1996).Ginseng (Panax ginseng C.A. Meyer) is a herb that belongs to the genus Ogawa and Ginseng. It has been used in Korea, China and Japan for over 2,000 years. It has been used for the purpose of preventing diseases and prolonging life span. The efficacy and efficacy of ginseng has been known so far as the anticancer effect, the immune function regulation effect, the anti-diabetic effect, the hyperfunction of the liver function, the improvement of the cardiovascular disorder, the anti-arteriosclerosis effect, the blood pressure control effect, the improvement of the menopausal disorder, Antioxidant activity, and antioxidant activity (Recent Ginseng Components and Efficacy, Korea Ginseng & Tobacco Research Institute, 56-112, 1996).
일반적으로 인삼은 그 가공방법에 따라 여러 가지로 분류할 수 있는데, 크게 수삼, 홍삼, 백삼, 태극삼으로 나눌 수 있다. 여기서 수삼은 경작지에서 재배한 인삼을 가공하지 않은 상태의 것을 말하며, 수삼을 쪄서 건조시킨 것을 홍삼, 수삼을 익히지 아니하고 건조시킨 것을 백삼, 수삼을 열수에 찌거나 데친 다음 건조시킨 것을 태극삼이라 한다.Generally, ginseng can be classified into various kinds according to its processing method, and can be divided into ginseng, red ginseng, white ginseng, and taekguk ginseng. Here, ginseng refers to a state in which ginseng cultivated on cultivated land has not been processed. The ginseng is steamed and dried, and the dried ginseng and ginseng are dried without boiling them. The ginseng is steamed or steamed in hot water and dried.
백삼은 통상 4∼6년근의 수삼을 박피하거나 혹은 박피하지 않은 상태에서 자연건조시키거나 또는 60℃ 이하로 열풍건조시켜 수분함량이 14% 이하가 되도록 한 것으로서, 박피한 것을 백삼이라고 하고 박피하지 않은 상태의 것을 피부백삼이라고 한다. 백삼은 건조시킨 형태에 따라 직삼, 반곡삼, 곡삼 등으로 구분되고, 제품의 색은 유백색이나 연노랑색을 나타내는데, 이러한 백삼을 원료로 하여 제조되는 제품으로는 인삼추출액, 인삼차, 인삼추출 과립제, 인삼 드링크제, 인삼 비누 등과 같은 식품, 약품, 화장품 등이 있다.White ginseng is normally dried for 4 to 6 years in the absence of peeling or peeling, or dried in hot air at 60 ° C or less to have a moisture content of 14% or less. The white ginseng is called peeled white ginseng The condition is called skin white ginseng. Ginseng extract, ginseng tea, ginseng extract granules, ginseng extract, ginseng extract, ginseng extract, ginseng extract, ginseng extract, and ginseng extract are classified according to the dried form. Food, medicine, and cosmetics such as alcoholic beverages, drinks, and ginseng soaps.
대한민국 등록특허 제10-1382113호에는 백삼 및 홍삼 다당체 파우더를 회수한 다음 1만 미만, 1만 이상 3만 미만, 3만 이상 10만 미만 및 10만 이상을 포함하는 추출물을 각각 한외여과로 분획하여 제조하는 피부 외용제 조성물이 기재되어 있다.In Korean Patent No. 10-1382113, white ginseng and red ginseng polysaccharide powders were recovered and then the extracts containing less than 10,000, 10,000 to 30,000, 30,000 to less than 100,000 and 100,000 or more were fractionated by ultrafiltration A composition for external application for skin is disclosed.
상기 백삼은 오랜 시간에 걸쳐 한방적으로 그 유용성이 입증되어 왔음에도 불구하고, 백삼의 불용성 다당체 및 진세노사이드 등에 의한 항산화 특성에 대해서는 활용된 바가 없다.Although the white ginseng has been proved useful for a long period of time, the antioxidant properties of white ginseng due to insoluble polysaccharides and ginsenosides have not been utilized.
상기한 배경기술로서 설명된 사항들은 본 발명의 배경에 대한 이해증진을 위한 것일 뿐, 이 기술분야에서 통상의 지식을 가진 자에게 이미 알려진 종래기술에 해당함을 인정하는 것으로 받아들여져서는 안 될 것이다.It should be understood that the foregoing description of the background art is merely for the purpose of promoting an understanding of the background of the present invention and is not to be construed as adhering to the prior art already known to those skilled in the art.
본 발명의 주된 목적은 백삼에서 유래한 진세노사이드 Rd, Rg3 및 Rg5를 유효성분으로 함유하여 항산화 효능을 나타내는 식품 조성물 및 약학 조성물을 제공하는 데 있다.The main object of the present invention is to provide a food composition and a pharmaceutical composition which contain antioxidant activity by containing ginsenosides Rd, Rg3 and Rg5 derived from white ginseng as an active ingredient.
본 발명의 또 다른 목적은 효소를 이용하여 진세노사이드 Rd, Rg3 및 Rg5 성분이 강화된 백삼 추출물의 제조방법을 제공하는 데 있다.It is still another object of the present invention to provide a method for preparing white ginseng extract having enhanced ginsenoside Rd, Rg3 and Rg5 components by using an enzyme.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 더욱 명확하게 된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
상기 목적을 달성하기 위하여 본 발명은 백삼에서 유래한 진세노사이드 Rd, Rg3 및 Rg5를 유효성분으로 함유하여 항산화 효능을 나타내는 것을 특징으로 하는 식품 조성물 및 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a food composition and a pharmaceutical composition characterized by exhibiting antioxidative activity, comprising ginsenoside Rd, Rg3 and Rg5 derived from white ginseng as an active ingredient.
또한, 본 발명은 다음의 단계를 포함하는 진세노사이드 Rd, Rg3 및 Rg5를 유효성분으로 포함하는 백삼 추출물의 제조방법을 제공한다.Further, the present invention provides a method for producing white ginseng extract comprising ginsenosides Rd, Rg3 and Rg5 as active ingredients, comprising the following steps.
(a) 백삼에 주정을 가하여 65~70℃에서 12시간 이상 추출하는 단계; (a) adding white ginseng to the white ginseng and extracting it at 65 to 70 ° C for 12 hours or more;
(b) 상기 추출물을 원심분리여과기로 여과한 후 여과액을 농축기에서 45~50℃로 4~6시간 동안 감압농축하여 농축액을 수득하는 단계;(b) filtering the extract with a centrifugal filter, and then concentrating the filtrate in a concentrator at 45 to 50 ° C under reduced pressure for 4 to 6 hours to obtain a concentrate;
(c) 상기 농축액의 2%(w/w) 효소를 투입하여 교반 용해시킨 후 120±5℃에서 10분간 가열하여 살균하고, 상기 살균액을 10,000rpm 이상의 원심분리여과기로 여과하는 단계; 및(c) adding 2% (w / w) enzyme of the concentrated solution, dissolving with stirring, sterilizing by heating at 120 ± 5 ° C for 10 minutes, filtering the sterilized solution with a centrifugal filter of 10,000 rpm or more; And
(d) 상기 여과액을 동결건조하여 수분함량 7% 이하로 분말화하는 단계.(d) lyophilizing the filtrate to a water content of 7% or less.
본 발명에 있어서 상기 백삼 추출물은 감압농축하여 고형분의 함량이 6 내지 12 브릭스(Brix)인 것을 사용할 수 있다. 상기 고형분의 함량을 6 내지 12 브릭스(Brix)로 조절하지 않으면 농도가 너무 진해서 발효가 잘되지 않고 겔화되는 문제가 발생할 수 있다.In the present invention, the white ginseng extract may be concentrated to a solid content of 6-12 brix by vacuum concentration. If the content of the solid content is not adjusted to 6 to 12 Brix, the concentration may be too high to cause a problem that the fermentation is not performed well and gelation occurs.
본 발명에 있어서, 상기 효소투입단계는 상기 농축액의 총중량에 0.1 내지 20%, 바람직하게는 2%(w/w)가 되도록 효소를 첨가하고 교반 용해시킨 후 120±5℃에서 10분간 가열하여 살균시킨다.In the present invention, the enzyme is added in an amount of 0.1 to 20%, preferably 2% (w / w) based on the total weight of the concentrate, stirred and dissolved, and then sterilized by heating at 120 ± 5 ° C. for 10 minutes .
본 발명에서 상기 효소는 펙티나제(pectinase)를 이용하며, 바람직하게는 Pectinex Ultra Pulp인 것을 특징으로 한다.In the present invention, the enzyme may be a pectinase, preferably Pectinex Ultra Pulp.
본 발명의 또 다른 양태에 따르면, 본 발명은 상기 백삼 추출물을 포함하는 약학 조성물 또는 식품 조성물을 제공한다.According to another aspect of the present invention, there is provided a pharmaceutical composition or food composition comprising the white ginseng extract.
본 발명에 있어서, 본 발명의 백삼 추출물의 배합비율은, 그 종류 및 배합되는 다른 성분의 종류나 양, 형태 등에 따라서 적당하게 선택할 수 있는데, 통상, 의약 또는 식품 전량에 대해, 본 발명의 백삼 추출물을 0.001 내지 20 중량%, 바람직하게는 0.01 내지 10 중량%를 포함할 수 있다.In the present invention, the mixing ratio of the white ginseng extract of the present invention can be appropriately selected depending on the kind and amount, shape, etc. of the kind and the other ingredients to be mixed. Usually, the white ginseng extract of the present invention By weight to 0.001 to 20% by weight, preferably 0.01 to 10% by weight.
본 발명의 조성물이 약학 조성물로 제조되는 경우, 통상적인 방법에 따라 약학 제형으로 제조될 수 있다. 제형의 제조에 있어서, 활성 성분을 담체와 함께 혼합 또는 희석하거나, 용기 형태의 담체 내에 봉입시키는 것이 바람직하다. 담체가 희석제로 사용되는 경우에는 활성 성분에 대한 담체, 부형제 또는 매질(medium)로 작용하는 고형, 반고형 또는 액상의 물질일 수 있다. 따라서, 제형은 정제, 환제, 분제, 새세이, 엘릭시르, 현탁제, 유제, 용액제, 시럽제, 에어로졸, 연질 또는 경질 젤라틴 캡슐제, 멸균 주사제, 멸균 분제 등의 형태일 수 있다. 본 발명의 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있다.When the composition of the present invention is prepared with a pharmaceutical composition, it can be prepared into a pharmaceutical formulation according to a conventional method. In the preparation of the formulations, it is preferred that the active ingredient is mixed with or diluted with the carrier, or enclosed in a carrier in the form of a container. When the carrier is used as a diluent, it may be a solid, semi-solid or liquid substance acting as a carrier, excipient or medium for the active ingredient. Thus, the formulations may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatine capsules, sterile injections, sterile powders and the like. The compositions of the present invention may be formulated using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal.
여기서, 본 발명의 약학 조성물은 경구, 경피, 피하, 정맥, 복강, 근육, 국소도포, 첩포 및 이온토포레시스(iontophoresis)를 포함한 여러 경로를 통해 투여될 수 있고, 이 중에서 국소 적용 및 경구투여가 바람직하다. 본 발명의 활성 성분의 실제 투여량은 치료할 질환, 투여 경로, 환자의 연령, 성별 및 체중, 및 질환의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.Herein, the pharmaceutical composition of the present invention can be administered through various routes including oral, transdermal, subcutaneous, intravenous, intraperitoneal, muscle, topical application, patch and iontophoresis, . The actual dosage of the active ingredient of the present invention should be determined in view of various factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease, But is not limited to.
본 발명의 조성물이 식품 조성물로 제조되는 경우, 유효성분으로서 본 발명에 따른 백삼추출물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 단당류, 예를 들어, 포도당, 과당 등; 이당류, 예를 들어 말토스, 수크로스, 올리고당 등; 및 다당류, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명에 따른 백삼추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.When the composition of the present invention is prepared as a food composition, it includes not only the white ginseng extract according to the present invention as an active ingredient but also components normally added in the production of food, for example, protein, carbohydrate, fat, And flavoring agents. Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides, such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavors (saccharin, aspartame, etc.) may be used as flavorings. For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .
본 발명에 따른 백삼 추출물은 펙티나제 효소를 이용하여 제조함으로써 백삼으로부터 유래한 진세노사이드 Rd, Rg3 및 Rg5 성분이 강화된 항산화 효능을 나타내는 식품 조성물 또는 약학 조성물로 다양하게 활용할 수 있다. The white ginseng extract according to the present invention can be variously used as a food composition or a pharmaceutical composition exhibiting antioxidative activity enhanced by the ginsenoside Rd, Rg3 and Rg5 components derived from white ginseng by using pectinase enzyme.
도 1은 본 발명에 따른 6brix 백삼 농축액의 효소처리에 따른 진세노사이드 함량을 분석한 그래프이다.
도 2는 본 발명에 따른 12brix 백삼 농축액의 효소처리에 따른 진세노사이드 함량을 분석한 그래프이다.
도 3은 본 발명에 따른 백삼 농축액의 효소처리 시간에 의한 DPPH radical 소거능을 나타낸 그래프이다.FIG. 1 is a graph showing an analysis of the content of ginsenoside according to the enzyme treatment of 6brix white ginseng concentrate according to the present invention.
FIG. 2 is a graph showing the content of ginsenoside according to the enzyme treatment of 12brix white ginseng concentrate according to the present invention.
FIG. 3 is a graph showing the DPPH radical scavenging ability of the white ginseng concentrate according to the enzyme treatment time according to the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
[[ 실시예Example 1] 백삼 추출물의 효소처리에 의한 특정성분 강화 성분 표준 제조공정 개발 1] Development of Standard Manufacturing Process of Specific Component Reinforcement Component by Enzyme Treatment of White Ginseng Extract
1. 진세노사이드 함량 분석 1. Analysis of ginsenoside content
진세노사이드 성분의 분석은 YoungLin YL9100를 이용하였고, 아세토니트릴(A액)과 물(B액)을 다음과 같은 기울기 조건으로 1.0 mL/분의 유속으로 흘려보내며 측정하였다(표 1). 하기 표 1은 진세노사이드 분석을 위한 HPLC 조건을 나타낸 것이다.The analysis of the ginsenoside components was carried out using Younglin YL9100, and the acetonitrile (liquid A) and water (liquid B) were flowed at a flow rate of 1.0 mL / min at the following slope conditions (Table 1). Table 1 below shows HPLC conditions for ginsenoside analysis.
2. 백삼 추출물의 효소처리에 의한 특정성분 강화 생산 공정2. Enhanced production process of white ginseng extract by enzymatic treatment
4년근 인삼을 금산 도매시장에서 기준 및 규격에 적합한 4년근 인삼을 확인한 후 선별구입하였다. 세척한 수삼을 60℃에서 2~3일 정도 건조기를 이용하여 건조된 수삼을 백삼 원료로 사용하였다. 백삼 원료를 7~8배의 주정(95%)을 가한 후, 65~70℃에서 12시간 이상씩 3~4회 추출하였다. 상기의 추출액을 12,000rpm 이상의 원심분리여과기로 여과한 후 여과액을 농축기에서 45~50℃로 4~6시간 동안 감압농축(고형분 60%이상)하였다. 제조된 백삼 농축액(고형분 60% 이상)을 각각 6brix 및 12brix로 각각 제조한 후 Pectinex Ultra Pulp 효소 2%(w/w)를 투입하여 37℃에서 반응시간 0, 6, 12, 24 시간 동안 교반시켜 용해하였다. 용해된 효소처리한 백삼시료를 120±5℃에서 10분간 가열하여 살균하고, 살균액을 10,000rpm 이상의 원심분리여과기로 여과하여 동결건조기를 이용하여 분말화하였다.4 - year - old ginseng was selected and purchased in the wholesale market of Jinshan after confirming the 4 - year - old ginseng suitable to the standards and specifications. The washed ginseng was dried at 60 ℃ for 2 ~ 3 days using a dried ginseng as white ginseng. The white ginseng raw materials were added 7 ~ 8 times of alcohol (95%) and then extracted 3-4 times at 65 ~ 70 ℃ for 12 hours or more. The extract was filtered through a centrifugal filter of 12,000 rpm or more, and the filtrate was concentrated under reduced pressure (solid content: 60% or more) at 45 to 50 ° C for 4 to 6 hours in a concentrator. The prepared white ginseng concentrate (60% or more of solid content) was prepared as 6brix and 12brix, respectively, and 2% (w / w) of Pectinex Ultra Pulp enzyme was added thereto and stirred at 37 ° C for 0, 6, 12 and 24 hours Lt; / RTI > The dissolved white ginseng samples were sterilized by heating at 120 ± 5 ° C for 10 minutes. The sterilized solution was filtered with a centrifugal filter of 10,000 rpm or more and pulverized using a freeze dryer.
① 백삼 추출물의 효소처리에 의한 특정성분 강화 성분 분획 진세노사이드 함량 (1) Specific components of the white ginseng extract by enzyme treatment Reinforcement component fraction Ginsenoside content
6brix 백삼 농축액의 효소처리에 따른 진세노사이드 함량을 분석하여 하기 표 2에 나타내었다. 진세노사이드 Rg1, Re, Rb1, Rd, Rg3, Rk1, Rg5의 7종의 함량을 측정한 결과 6brix 백삼 농축물에서의 Rg1, Rb1, Re, Rk1의 함량은 무처리구 6brix 백삼 농축물에서 가장 높은 함량을 나타내었고 효소처리 시간에 따라 함량이 감소하는 경향을 확인할 수 있었다. Rd, Rg3, Rg5 함량에서는 무처리구 6brix 백삼 농축물보다 24시간 Pectinex Ultra Pulp 효소 처리한 시료에서 각각 2.9, 8.5, 2.6배 이상 높아지는 것을 확인할 수 있었으며, 특히 24시간 Pectinex Ultra Pulp 효소 처리한 시료에서 Rg3 함량이 5.89 mg/g으로 가장 많이 증가하는 것을 확인하였다(표 2, 도 1). The content of ginsenoside according to the enzyme treatment of 6brix white ginseng concentrate was analyzed and shown in Table 2 below. The content of Rg1, Rb1, Re, and Rk1 in the 6brix white ginseng concentrate was the highest in the untreated 6brix white ginseng concentrate as a result of measuring 7 kinds of ginsenosides Rg1, Re, Rb1, Rd, Rg3, Rk1, And the content was decreased with the enzyme treatment time. Rd, Rg3, and Rg5 were 2.9, 8.5, and 2.6 times higher than those of the 6brix white ginseng concentrate for 24 hours, respectively. Especially, the content of Rg3 in 24 hour Pectinex Ultra Pulp enzyme treated samples Was 5.89 mg / g (Table 2, Fig. 1).
12brix 백삼 농축액의 효소처리에 따른 진세노사이드 함량을 분석하여 하기 표 3에 나타내었다. 12brix 백삼 농축물에서의 Rg1, Rb1, Rk1의 함량은 무처리구 12brix 백삼 농축물에서 가장 높은 함량을 나타내었고, 효소처리 시간에 따라 함량이 감소하는 경향을 확인할 수 있었다. Rd, Rg3, Rg5 함량에서는 무처리구 12brix 백삼 농축물보다 24시간 Pectinex Ultra Pulp 효소 처리한 시료에서 2배 이상 높아지는 것을 확인할 수 있었다(표 3, 도 2). The content of ginsenoside according to the enzyme treatment of the 12brix white ginseng concentrate was analyzed and shown in Table 3 below. The content of Rg1, Rb1, and Rk1 in 12brix white ginseng concentrate was highest in the 12brix white ginseng concentrate without treatment, and the content decreased with enzyme treatment time. The contents of Rd, Rg3 and Rg5 were more than 2 times higher than those of the 12brix white ginseng concentrate treated with Pectinex Ultra Pulp enzyme for 24 hours (Table 3, Fig. 2).
[[ 실험예Experimental Example 1] 백삼 추출물의 효소처리에 의한 특정성분 강화 성분 분획 활성 평가 1] Evaluation of Fractional Activity of Specific Ingredients Reinforced by Enzyme Treatment of White Ginseng Extract
1. One. DPPHDPPH radical radical 소거능Scatters
건강기능식품 기능성평가 총 항산화능 시험방법 중 Blois(1958)의 방법에 의한 DPPH (1,1 -diphenyl-2-picryl hydrazyl)에 대한 수소공여 효과를 측정하여 전자공여능(EDA; electron donating ability)으로 나타내었다. 즉, EtOH에 용해한 0.3 mM의 DPPH 용액 100 ㎕와 시료 용액 100 ㎕를 혼합하여 교반하였다. 이 혼합 시료를 암소에서 30분간 반응시킨 후 517 ㎚에서 흡광도를 측정하였다. 500 ㎍/ml 처리하였을 때 효소 처리한 시료에서 처리시간에 길어짐에 따라 소거활성이 낮아지는 것을 확인하였고, 무처리구 보다 6brix, 12brix 백삼 농축물 6시간 Pectinex Ultra Pulp 효소 처리한 시료에서 높은 소거활성을 나타내었다(도 3).Functional evaluation of health functional foods The effect of hydrogen donation on DPPH (1,1-diphenyl-2-picryl hydrazyl) by the method of Blois (1958) was tested by electron donating ability Respectively. That is, 100 μl of a 0.3 mM DPPH solution dissolved in EtOH and 100 μl of a sample solution were mixed and stirred. After the reaction mixture was reacted in a dark place for 30 minutes, the absorbance was measured at 517 nm. 500 ㎍ / ml treatment, it was confirmed that the scavenging activity decreased with increasing the treatment time. In the samples treated with Pectinex Ultra Pulp enzyme for 6 hours, 6brix, 12brix white ginseng concentrate showed higher scavenging activity (Fig. 3).
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (3)
(b) 상기 추출물을 원심분리여과기로 여과한 후 여과액을 농축기에서 45~50℃로 4~6시간 동안 감압농축하여 고형분의 함량이 6 내지 12 브릭스(Brix)인 농축액을 수득하는 단계;
(c) 상기 농축액의 2%(w/w) 효소를 투입하여 교반 용해시킨 후 120±5℃에서 10분간 가열하여 살균하고, 상기 살균액을 10,000rpm 이상의 원심분리여과기로 여과하는 단계; 및
(d) 상기 여과액을 동결건조하여 수분함량 7% 이하로 분말화하는 단계를 포함하는 것을 특징으로 하는 진세노사이드 Rd, Rg3 및 Rg5 함량이 강화된 백삼 추출물의 제조방법.
(a) adding white ginseng to the white ginseng and extracting it at 65 to 70 ° C for 12 hours or more;
(b) filtering the extract with a centrifugal filter, and then concentrating the filtrate in a concentrator at 45 to 50 ° C under reduced pressure for 4 to 6 hours to obtain a concentrate having a solid content of 6 to 12 Brix;
(c) adding 2% (w / w) enzyme of the concentrated solution, dissolving with stirring, sterilizing by heating at 120 ± 5 ° C for 10 minutes, filtering the sterilized solution with a centrifugal filter of 10,000 rpm or more; And
(d) lyophilizing the filtrate to a water content of 7% or less. The method of claim 1, wherein the ginsenoside Rd, Rg3 and Rg5 contents are enhanced.
A food composition characterized by exhibiting an antioxidative effect containing, as an active ingredient, white ginseng extract having enhanced contents of ginsenosides Rd, Rg3 and Rg5 produced by the production method of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170066486A KR101929664B1 (en) | 2017-05-30 | 2017-05-30 | Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170066486A KR101929664B1 (en) | 2017-05-30 | 2017-05-30 | Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180131652A KR20180131652A (en) | 2018-12-11 |
| KR101929664B1 true KR101929664B1 (en) | 2018-12-18 |
Family
ID=64671899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170066486A Active KR101929664B1 (en) | 2017-05-30 | 2017-05-30 | Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101929664B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020091479A1 (en) | 2018-10-31 | 2020-05-07 | 주식회사 엘지화학 | Lithium electrode and lithium secondary battery comprising same |
| CN116200447A (en) * | 2023-02-20 | 2023-06-02 | 南京珼瑞斯生物医药科技有限公司 | A method for preparing Ginseng radix Rubri Leptoradix extract rich in ginsenoside Rg3 and Rg5 by pectase |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101330864B1 (en) | 2013-04-02 | 2013-11-18 | 재단법인 금산국제인삼약초연구소 | Preparation for fermented-red gingseng or fermented-gingseng containing increased ginsenoside rd using pectinase |
-
2017
- 2017-05-30 KR KR1020170066486A patent/KR101929664B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101330864B1 (en) | 2013-04-02 | 2013-11-18 | 재단법인 금산국제인삼약초연구소 | Preparation for fermented-red gingseng or fermented-gingseng containing increased ginsenoside rd using pectinase |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180131652A (en) | 2018-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102458434B (en) | Compositions for increasing the bioavailability of saponins | |
| JP2019065056A (en) | Obesity inhibiting composition | |
| KR102150162B1 (en) | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof | |
| CN101842380B (en) | Eriocitrin-containing material, production method of eriocitrin-containing material, and food, drink, drug, and cosmetic including eriocitrin-containing material | |
| CN114271489A (en) | A kind of anti-glycation health food composition | |
| KR101617590B1 (en) | Antiobesity Food Composition Comprising Extract of Aronia, Acaiberry and Stevia | |
| KR101929664B1 (en) | Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof | |
| CN102217755B (en) | Production method of Kusamaki seed extract and product | |
| KR20100130020A (en) | Composition containing black ginseng and extracts thereof prepared by a novel manufacturing method that does not contain carcinogenic substances such as benzopyran | |
| KR102386574B1 (en) | Health functional drink comprising fermented steam-dreid ginseng berry | |
| CA2904636C (en) | Method of preparing a muscadine pomace extract | |
| KR101409168B1 (en) | Method for manufacturing red ginseng extract with enhanced function and the extact thereof | |
| KR101988102B1 (en) | Composition for anti-oxidation containing the complex extracts of white ginseng, Agrimonia pilosa, Salvia miltiorrhiza and Solidago virgaurea | |
| KR101962169B1 (en) | Manufacturing method of an extract enriched with ginsenoside Rg3 from red ginseng and food composition containing it | |
| KR20200120801A (en) | Red Ginseng Extract comprising Saponin and high purity Acidic Polysaccarride, Manufacturing method thereof and Healty Food containing the same | |
| CN109287916A (en) | A kind of preparation method of Sessileflower Acanthopanax Bark extracting solution and its beverage | |
| KR102395717B1 (en) | Beverage composition comprising active ingredients of black garlic and red ginseng, and manufacturing method thereof | |
| JP5560445B2 (en) | Eating and drinking composition and medicinal composition | |
| KR102173223B1 (en) | Food composition containing extract of roasted codonopsis lanceolata or roasted platycodon grandiflorum | |
| KR101839209B1 (en) | Composition for anti-oxidation and anti-diabetes comprising polysaccharide and ginsenoside of white ginseng | |
| CN118638080B (en) | Method for extracting high-purity and high-biologically active natural vitamin C from roxburghii | |
| KR102898495B1 (en) | Composition for fatigue recovery comprising the Cervus Parvum Cornu extract as active ingredients | |
| KR102403393B1 (en) | Hydrated Herb Seed Composite Containing Ginsenoside And Food Composition Comprising Thereof | |
| KR20130074118A (en) | Ginseng prosapogenin high concentration containing ginseng berry preparation using sonication and process for thereof | |
| KR20250162683A (en) | Jinseng natto having thrombolytic activity and the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| P14-X000 | Amendment of ip right document requested |
St.27 status event code: A-5-5-P10-P14-nap-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| P14-X000 | Amendment of ip right document requested |
St.27 status event code: A-5-5-P10-P14-nap-X000 |
|
| P16-X000 | Ip right document amended |
St.27 status event code: A-5-5-P10-P16-nap-X000 |
|
| Q16-X000 | A copy of ip right certificate issued |
St.27 status event code: A-4-4-Q10-Q16-nap-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 8 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |


